

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Chaoju Eye Care Holdings Limited**  
**朝聚眼科醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2219)**

**POSITIVE PROFIT ALERT**

This announcement is made by Chaoju Eye Care Holdings Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on a preliminary review of the unaudited consolidated management accounts of the Company for the six months ended June 30, 2023 and the information currently available to the Board, the Group expects to record a revenue in the range of RMB670 million to RMB720 million for the six months ended June 30, 2023, representing an increase of approximately 26% to 35%, as compared to a revenue of RMB532.7 million for the corresponding period in 2022; and a net profit in the range of RMB140 million to RMB155 million for the six months ended June 30, 2023, representing an increase of approximately 38% to 52%, as compared to a net profit of RMB101.8 million for the corresponding period in 2022.

Based on information currently available, the Board considers that such expected increases are primarily attributable to, among other things, the following reasons:

- (i) the recovery of demand for ophthalmic services, owing to the increased corporate efficiency which enhanced the Group’s reception capacity for patient visits, the recovery of the industry and the general economic environment in the PRC after the COVID-19 pandemic, which led to an overall increase of the Group’s revenue; and
- (ii) the growth in net profit due to higher gross profit margin resulted from the expansion of consumer ophthalmic services and basic ophthalmic services businesses after the COVID-19 pandemic as well as better economies of scale so derived.

The information contained in this announcement is only a preliminary assessment made by the management of the Company based on the unaudited consolidated management accounts of the Company for the six months ended June 30, 2023 and the information currently available to the Board as of the date of this announcement, which has not been audited or reviewed by the auditors of the Company and/or the audit committee of the Board. Details of the unaudited interim results of the Company for the six months ended June 30, 2023, which may differ from the figures and information provided in this announcement, are expected to be disclosed in the forthcoming interim results announcement by the end of August 2023 and the 2023 interim report by the end of September 2023.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Chaoju Eye Care Holdings Limited**  
**ZHANG Bozhou**  
*Chairman*

Hong Kong, August 21, 2023

*As of the date of this announcement, the Board of Directors of the Company comprises Mr. ZHANG Bozhou as Chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. KE Xian, Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Li as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.*